Sutib 50MG Capsule, containing the active ingredient Sunitinib at a dosage of 50mg, is a targeted therapy medication primarily used in the treatment of certain types of cancer, including renal cell carcinoma and gastrointestinal stromal tumors. This oral capsule is designed to inhibit tumor growth by blocking specific proteins that promote cancer cell proliferation and angiogenesis, the process through which tumors develop their blood supply. Sutib is composed of Sunitinib malate, which is a potent inhibitor of multiple receptor tyrosine kinases, making it effective in disrupting the signaling pathways that cancer cells rely on for survival and growth. The medication is typically prescribed for patients who have not responded to other treatments, providing a crucial option in the management of advanced cancer. As a result, Sutib 50MG Capsule plays a significant role in improving patient outcomes and quality of life in oncology.